Siegfried Shares Jump After Purchase of Noramco and Extractas Drug-Substance Operations
Siegfried's stock climbed more than 9% following the announcement that the Swiss life sciences firm will acquire drug-substance operations from Noramco and Extractas Bioscience. The transaction adds three sites across Delaware, Georgia and Tasmania, increases Siegfried’s U.S. facility count to five, and links early-phase development platforms with …